

Marked Truncal Acne Response to Sarecycline Monotherapy in Different Ethnicities

Angela Yen Moore^{1,2}, Stephen Moore^{1,3}, Luke Moore¹, Ayman Grada⁴, Stephen K Tying³

¹Arlington Research Center, Arlington, TX, USA; ²Baylor University Medical Center, Dallas, TX, USA

³Department of Dermatology, The University of Texas McGovern Medical School, Houston, TX, USA; ⁴Grada Dermatology Research LLC, Chesterbrook, PA, USA

INTRODUCTION

- 60-70% of patients present with acne on the trunk.¹
- Since severity of truncal acne does not correlate with severity of facial acne, the psychosocial burden and physical pain and bleeding of truncal acne cannot be underestimated.²
- Oral antibiotics are the mainstay treatment for moderate-to-severe acne vulgaris.
- Sarecycline, a **narrow-spectrum** tetracycline-class drug, is FDA-approved for moderate-to-severe acne vulgaris in patients 9 years of age and older.
- Sarecycline exhibits potent anti-inflammatory activity and activity against *C. acnes* but reduced activity against Gram-negative bacteria commonly found in the gut; these characteristics may contribute to its low potential for antibiotic resistance and favorable safety and tolerability profile.³
- Significant improvement in truncal acne, using IGA assessments, was reported with sarecycline in Phase 3 clinical trials.^{4,5}

METHODS

- We present 2 patients treated with sarecycline monotherapy for 3 months.
- At baseline, weeks 3, 6, 9 and 12, we assessed IGA scores and lesion counts change of the trunk.

Baseline Data

Demographics	Skin Phototype	Truncal IGA	Truncal lesion count*	Facial lesion count*
14 yo White male	2	4	47	8
13 yo Hispanic female	4	3	29	28

* Inflammatory lesions (papules and pustules)

14-year-old White Male

Baseline; IGA 4



Chest



Back

Week 12; IGA 1



13-year-old Hispanic Female

Baseline; IGA 3



Chest



Back

Week 12; IGA 1



RESULTS

Inflammatory Lesion Count Reduction

Demographics	Baseline	3 Wks	6 Wks	9 Wks	12 Wks
14 yo White male	47	22 (53%)	8 (83%)	1 (98%)	2 (96%)
13 yo Hispanic female	29	16 (45%)	4 (86%)	2 (93%)	3 (90%)

- No side effects of special interest for tetracycline-family antibiotics, including nausea, diarrhea, esophagitis, pseudotumor cerebri, blurry or double vision, dizziness, vertigo, or blue-gray pigmentation, were observed.

CONCLUSIONS

- This case series shows rapid improvement in IGA and reduction inflammatory lesion count with oral sarecycline, and confirms previously reported significant improvement of truncal acne in Phase 3 clinical trials

CLINICAL IMPLICATIONS

- Sarecycline is an effective narrow-spectrum antibiotic alternative that can be utilized in treating truncal acne, especially when topical agents are challenging for the patients to apply due to surface area and location

REFERENCES

- Del Rosso JQ, Stein-Gold L, Lynde C, Tanghetti E, Alexis AF. Truncal Acne: A Neglected Entity. *J Drugs Dermatol*. 2019;18(12):205-1208.
- Tan J, Beissert S, Cook-Bolden F, et al. Impact of facial and truncal acne on quality of life: A multi-country population-based survey. *JAAD International*. 2021;3:102-110. doi:10.1016/j.jdin.2021.03.002
- Bunick CG, Keri J, Tanaka SK, et al. Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation. *Antibiotics (Basel)*. 2021;10(4):439. doi:10.3390/antibiotics10040439
- Moore A, Green LJ, Bruce S, et al. Once-daily oral sarecycline 1.5 mg/kg/day is effective for moderate to severe acne vulgaris: Results from two identically designed, phase 3, randomized, double-blind clinical trials. *Journal of drugs in dermatology: JDD*. 2018;17(9):987-996.
- Del Rosso JQ, Stein Gold L, Baldwin H, et al. Management of Truncal Acne With Oral Sarecycline: Pooled Results from Two Phase-3 Clinical Trials. *J Drugs Dermatol*. 2021;20(6):634-640. doi:10.36849/JDD.2021.6204

Disclosures: Research grant from Almirall, LLC.